American Society of Hirudotherapy

Metabolic Syndrome (Investigational Adjunct)

Investigational adjunct to lifestyle modification in metabolic syndrome; no clinical study in metabolic syndrome identified; weight loss, dietary modification, and pharmacotherapy remain primary.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 12, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for metabolic syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for metabolic syndrome is investigational.
What evidence exists?
Tier C (investigational). No clinical study of leech therapy in people with metabolic syndrome was identified in PubMed or Europe PMC; research found so far includes a rat study and small reports of blood lipids in other patient groups, and a Russian medical book describes a report on people with type 2 diabetes and obesity treated with leeches among other methods, with no comparison group named (see “What the books describe” below). Evidence-based management of metabolic syndrome per AHA/ACC guidelines: lifestyle modification (weight loss 5-10 percent, Mediterranean or DASH diet, 150 minutes/week aerobic exercise plus resistance training), treatment of individual components (statin for dyslipidemia, ACE inhibitor or ARB for hypertension, metformin or GLP-1 receptor agonist for insulin resistance/prediabetes/type 2 diabetes), and cardiovascular risk stratification.
Main risks
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Worsening of glycemic control or blood pressure
  • Local skin infection or, rarely, Aeromonas infection (higher risk in diabetes)
  • Allergic reaction to leech saliva (uncommon)
  • Delayed wound healing in patients with poorly controlled diabetes
  • Risk of vasovagal episode in patients with autonomic dysfunction
  • Substitution for lifestyle modification and proven pharmacologic therapy
  • Delay of statin, antihypertensive, or GLP-1 receptor agonist therapy
Who should not consider this
  • Patients with poorly controlled diabetes (HbA1c >9 percent)
  • Patients with peripheral arterial disease severe stenosis or diabetic foot ulcers
  • Patients with active cardiovascular event (recent MI, unstable angina, decompensated heart failure)
  • Patients on anticoagulants, with hemophilia, or with anemia
  • Pregnant patients
  • Patients who have not engaged with lifestyle modification or evidence-based pharmacotherapy
What to ask your clinician
  • What is my 10-year cardiovascular risk (ASCVD score)?
  • Have I been started on appropriate evidence-based therapy (statin, ACE/ARB, metformin, GLP-1)?
  • Am I a candidate for a GLP-1 receptor agonist for weight loss and cardiovascular protection?
  • Have I had nutrition and exercise counseling?
  • What evidence specifically supports leech therapy for metabolic syndrome?
  • How will treatment be monitored (HbA1c, blood pressure, lipids, weight)?
  • What is the cost and is it covered by insurance? (typically not covered)
When to seek urgent care
  • Chest pain, shortness of breath, or pressure (possible cardiac event)
  • New numbness, weakness, or slurred speech (possible stroke)
  • Severe abdominal pain (possible pancreatitis from severe hypertriglyceridemia)
  • Diabetic foot ulcer or new skin breakdown on the feet
  • Spreading redness, warmth, pus, or red streaks (cellulitis)
  • Fever above 38.0 C / 100.4 F or chills
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or tongue swelling, throat tightness, or breathing difficulty

What this does NOT mean

  • This is NOT FDA-cleared for metabolic syndrome.
  • No study in people with metabolic syndrome establishes efficacy versus statin, antihypertensive, metformin, or GLP-1 receptor agonist therapy; animal data and small lipid reports do NOT.
  • It does NOT substitute for lifestyle modification (diet, exercise, weight loss), which is the foundation of management.
  • It does NOT address individual cardiovascular risk factors that require pharmacologic treatment.
  • It does NOT mean leech application is safe in patients with poorly controlled diabetes or peripheral arterial disease.

Clinical Profile

Category
Other
ICD-10
E88.81
Safety tier
Medium

Evidence Summary

Metabolic syndrome (NCEP ATP III: at least 3 of abdominal obesity, elevated triglycerides, low HDL, hypertension, impaired fasting glucose) is managed by intensive lifestyle modification (Mediterranean diet, exercise, weight loss) and component-specific pharmacotherapy. No clinical study of leech therapy in patients with metabolic syndrome was identified in PubMed, Europe PMC or ClinicalTrials.gov; use is investigational only. Related data include one 2026 rat study of hirudotherapy in diet-induced metabolic syndrome (Bilden et al.) and small, low-quality Russian reports of blood lipids after leech therapy in cardiac or hyperlipidemic patients (Isakhanian 1989/1991, n=20; Zhernov and Zubarkina 2013, n=63), none in a metabolic-syndrome population. The 2004 monograph by Baskova and Isakhanyan also retells a Russian report on patients with type 2 diabetes and obesity treated with leeches among other methods, with no comparison group named (see “What the books describe” below). Proposed effects on waist circumference, triglycerides, or insulin resistance are speculative and would be heavily confounded by concurrent lifestyle changes, and the lipase and cholesterol-esterase activity of leech salivary secretion, the mechanistic finding most relevant to the lipid components, comes from laboratory work (Baskova and Isakhanyan 2004); no study of this mechanism in patients was identified.

What the books describe

Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.

  • The words “metabolic syndrome” appear neither in the book by Baskova and Isakhanyan nor in the book by Michalsen et al.; closest to the topic in Baskova and Isakhanyan are an observation of patients with type II diabetes and obesity, blood tests (cholesterol, triglycerides) after hirudotherapy, and a mention of obesity in the historical survey[B1][B3].
  • Konstantinova and Stalmakov (1999), as retold by Baskova and Isakhanyan, used hirudotherapy together with other methods in 26 patients with type II diabetes and obesity of varying degree; according to the description, it was possible to lower the doses of blood-sugar-lowering sulfonamides (in some patients to stop them), to normalize body weight and to improve well-being[B1].
  • The authors of the book themselves note that this work does not state the area of application; the number of leeches, the scheme, a comparison group and the follow-up period are likewise not named in the retelling, and how to separate the contribution of the leeches from that of the “other methods of therapy” is not clear from the text[B1].
  • Apart from the work of Konstantinova and Stalmakov, obesity is named in the book as a condition in which leeches were used only in the historical survey (a paragraph on the use of the method in the United States): among the diseases for which leeches were used in the past, obesity is named too[B1].
  • Baskova and Isakhanyan discuss blood tests after hirudotherapy mainly in patients with atherosclerosis of the vessels of the heart and brain, with or without raised blood pressure: they write that hirudotherapy lowers cholesterol and low-density lipoproteins, but the observations presented are not sufficient to judge a marked anti-atherosclerotic effect[B1].
  • Michalsen et al. (chapter 8, “Contraindications,” Flecken and Michalsen) write that the usually harmless leech bite can cause local complications in patients with diseases in which wound healing is impaired, for example diabetes mellitus; and in the appendix to the book (patient information and consent) the list of contraindications includes poor wound healing in the past, which may be associated, for example, with poorly controlled diabetes mellitus and obesity[B3].
  • Among the contraindications listed in the book by Baskova and Isakhanyan (their list is longer) are hemophilia, hemorrhagic diatheses, anemias and the simultaneous use of anticoagulants; Michalsen et al. (chapter 8, “Contraindications,” Flecken and Michalsen) call hemophilia and the use of anticoagulants an absolute contraindication, and in anemia, in their words, treatment involving blood loss is generally contraindicated[B1][B3].

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Diabetic ketoacidosis or HHS (treat first)
  • Significant hepatic dysfunction (Child-Pugh B/C)
  • Active cholecystitis or pancreatitis

Related Conditions

References

  • [B1]

    Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]

    Москва: Монолит(2004)https://search.rsl.ru/ru/record/01007959553

    Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.

  • [B3]

    Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy

    Stuttgart — New York: Thieme(2007)https://books.google.com/books?vid=ISBN9781588905635

    ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.

The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.